tiprankstipranks
Trending News
More News >

OncoCyte price target raised to $8 from $5 at Lake Street

Lake Street analyst Thomas Flaten raised the firm’s price target on OncoCyte (OCX) to $8 from $5 and keeps a Buy rating on the shares after the company announced CMS “substantially” increased the reimbursed rate for GraftAssureCore to $2,753. The firm believes this “augurs well” for future GraftAssureDx pricing, so it has raised estimates, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue